Latest Breaking News On - Bhagirathbhai dholaria - Page 1 : comparemela.com

Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLL

Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.

Bhagirathbhai dholariaDivision of hematologyVanderbilt university medical center

Poseida Therapeutics (PSTX) Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

Poseida Therapeutics (PSTX) Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesRajesh belaniBhagirathbhai dholariaSyed rizviPoseida therapeutics incClinical developmentAmerican association for cancer researchVanderbilt ingram cancer centerPoseida therapeuticsAmerican associationCancer researchAnnual meetingAssociate professorChief medical officerSubgroup data

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

/PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with.

San diegoUnited statesSyed rizviRajesh belaniBhagirathbhai dholariaPoseida therapeutics incVanderbilt ingram cancer centerDrug administrationPrnewswire poseida therapeutics incClinical developmentAmerican association for cancer researchAmerican associationCancer researchAnnual meetingAssociate professorChief medical officer

Dr Dholaria on the Investigation of Noncovalent BTK Inhibitors in CLL

Bhagirathbhai Dholaria, MBBS, discusses the ongoing evaluation of noncovalent BTK inhibitors in patients with chronic lymphocytic leukemia.

Bhagirathbhai dholariaDivision of hematology oncologyVanderbilt ingram cancer centerPatients with chronic lymphocytic leukemiaNoncovalent btk inhibitors

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesKristin yaremaBhagirathbhai dholariaBrian truongStacey cranertPrnewswire poseida therapeutics incAmerican society of hematologyPoseida therapeutics incVanderbilt ingram cancer centerExchange commissionTherapeutics presents positive early resultsRelapsed refractory multiple myelomaAmerican societySan diegoCell therapyAssociate professor